Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

LY146032: activity and resistance development in vitro.

R P Mouton1, S L Mulders

  • 1Department of Medical Microbiology, University Hospital Leiden, The Netherlands.

The Journal of Antimicrobial Chemotherapy
|October 1, 1987
PubMed
Summary

LY146032, a novel lipopeptide antibiotic, demonstrated broad-spectrum activity against Gram-positive bacteria, including resistant strains. While resistance developed to all tested antibiotics, LY146032 showed promising bactericidal effects against specific pathogens.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Susceptibility of ceftazidime and other cephalosporins to a range of beta-lactamases and their potential as inducing agents.

The Journal of antimicrobial chemotherapy·2009
Same author

Penicillin tolerance and treatment failure in group A streptococcal pharyngotonsillitis.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·1996
Same author

A proposed standard for MIC-MBC laboratory techniques to detect penicillin tolerance in group A streptococci.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·1996
Same author

Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro.

Journal of medical microbiology·1995
Same author

Low prevalence of penicillin tolerance in group A streptococci.

The Journal of antimicrobial chemotherapy·1995
Same author

A comparison of pefloxacin/metronidazole and doxycycline/metronidazole in the treatment of laparoscopically confirmed acute pelvic inflammatory disease.

European journal of obstetrics, gynecology, and reproductive biology·1993

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Antibiotic resistance is a growing global health threat, necessitating the development of new antimicrobial agents.
  • Gram-positive bacteria, including Staphylococcus spp. and Streptococcus faecalis, are significant causes of hospital-acquired infections.
  • Existing antibiotics like vancomycin and teicoplanin face challenges with emerging resistance.

Purpose of the Study:

  • To evaluate the in vitro activity of LY146032, a novel lipopeptide antibiotic, against a panel of clinical isolates.
  • To compare the efficacy of LY146032 with established antibiotics: vancomycin, teicoplanin, cefamandole, and ciprofloxacin.
  • To assess the potential for resistance development to LY146032 and other agents.

Main Methods:

Related Experiment Videos

  • Antimicrobial susceptibility testing was performed on 107 clinical isolates, including methicillin-susceptible and methicillin-resistant Staphylococcus spp., Streptococcus faecalis, and Corynebacterium spp.
  • Bactericidal activity was assessed for LY146032 and ciprofloxacin against Streptococcus faecalis.
  • Resistance development was studied through serial transfer experiments with ten selected strains to determine minimum inhibitory concentration (MIC) changes.

    • Main Results:

    • All tested staphylococci were susceptible to LY146032, vancomycin, teicoplanin, and ciprofloxacin. Some methicillin-resistant strains showed resistance to cefamandole.
    • LY146032 and ciprofloxacin exhibited bactericidal activity against Streptococcus faecalis.
    • A stable, greater than or equal to eight-fold increase in MIC was observed against all tested agents, indicating variable resistance development. Simultaneous resistance to other antibiotics occurred in 11/200 tests.

    Conclusions:

    • LY146032 demonstrates potent in vitro activity against a range of Gram-positive bacteria, including resistant strains.
    • The lipopeptide antibiotic shows bactericidal potential against Streptococcus faecalis.
    • While resistance can develop to LY146032, its profile warrants further investigation as a potential therapeutic agent.